69,097 results match your criteria Libman-Sacks Endocarditis


Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.

Clin Rheumatol 2019 Jan 16. Epub 2019 Jan 16.

Department of Pediatric Rheumatology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Objectives: This study was conducted to analyze clinical characteristics, laboratory data, disease activity, and outcome of juvenile systemic lupus erythematosus (jSLE) patients from southern Turkey.

Methods: Fifty-three patients with jSLE diagnosed according to the revised American College of Rheumatology 1997 criteria between January 2005 and June 2018 were included in the present study.

Results: The median age at the diagnosis was 12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04433-4DOI Listing
January 2019

Hypertrophic Lichen Planus Mimicking Verrucous Lupus Erythematosus.

Cureus 2018 Nov 6;10(11):e3555. Epub 2018 Nov 6.

Dermatologist, San Diego Family Dermatology, San Diego, USA.

Lichen planus is an inflammatory skin condition that can affect the hair, mucous membranes, nails, and skin. Cutaneous lichen planus typically presents as papules that are planar, polygonal, pruritic, and purple. Subtypes of lichen planus include actinic, annular, atrophic, eruptive, follicular, hypertrophic, inverse, linear, palmoplantar, pemphigoides, pigmentosus, ulcerative, vesiculobullous, and vulvovaginal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324858PMC
November 2018

Sub-acute Cardiac Tamponade as an Early Clinical Presentation of Childhood Systemic Lupus Erythematosus: A Case Report.

Cureus 2018 Oct 22;10(10):e3478. Epub 2018 Oct 22.

Surgery, Jinnah Sindh Medical University, Karachi, PAK.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple systems by the process of inflammation and formation of auto-antibodies. When it presents in childhood, it is referred to as childhood systemic lupus erythematosus (cSLE). Cardiac tamponade is a rare but potentially lethal complication of cSLE, even rarer as an initial presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318088PMC
October 2018

Therapy Side Effects in Systemic Lupus Erythematosus.

Curr Health Sci J 2018 Jul-Sep;44(3):316-321. Epub 2018 Jul 15.

Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Romania.

Glucosteroids (GS) are widely used drugs for various inflammatory pathologies (Nephrotic syndrome, Proliferative glomerulonephritis, Extramembrane glomerulonephritis, Nephropathy of the Nodous Poliarterita (PAN), Nephropathy from purple Henoch-Schonlein, lupus nephropathy (LN), Acute adrenal insufficiency Waterhouse-Friederichsen, Chronic adrenal insufficiency Addison, Systemic Lupus Erythematosus (SLE), Polymyositis and dermatomyositis, Chronic granulomatosis, Crohn's disease, Hemorrhagic rectocolitis, Hemolytic anemias, Acute leukemias and chronic lymphocytic leukemia, Hodgkin's lymphoma). Although they are prescribed for their anti-inflammatory and immunosuppressive properties, they also have many side effects, hyperglycemia being one of the most common and representative, which is why these drugs need careful monitoring when administered over the long term. This paper presents the case of a 39 year old patient diagnosed with systemic lupus erythematosus (SLE) with class IV lupus nephropathy (LN) who developed numerous complications due to the pathogenic side effects: diabetes, amenorrhea, recurrent infections, and depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12865/CHSJ.44.03.18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311221PMC

Systemic Lupus Erythematosus with Linear IgA Bullous Dermatosis and Renal Vascular Lesions: An Extremely Rare Association.

Indian J Nephrol 2018 Nov-Dec;28(6):465-467

Department of Pathology, St. John's Medical College, Bengaluru, Karnataka, India.

We report a rare case of systemic lupus erythematosus presenting initially with cutaneous manifestations of linear IgA bullous dermatosis. Later the patient developed renal abnormalities due to thrombotic microangiopathy and lupus nephritis with inflammatory necrotizing vasculitis. Paucity of immune deposits was observed on Immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_200_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309391PMC
January 2019

Urinary Neutrophil Gelatinase-Associated Lipocalin and Urinary Soluble CXCL16 as Biomarkers of Activity in Pediatric Lupus Nephritis.

Indian J Nephrol 2018 Nov-Dec;28(6):427-432

Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University, Tanta, Egypt.

One of the challenges of treating patients with lupus nephritis (LN) is to assess disease activity. The aim of this study was to measure the urinary neutrophil gelatinase-associated lipocalin (uNGAL) and urinary soluble chemokine (C-X-C motif) ligand 16 (CXCL16) levels in children and adolescents with systemic lupus erythematosus (SLE) and investigate whether they are elevated in active LN. This study was conducted on 80 patients diagnosed as SLE by the Systemic Lupus International Collaborating Clinics criteria and 60 apparently healthy individuals as controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_265_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309382PMC
January 2019

Epidemiologic Profile of Erectile Dysfunction in Patients with Systemic Lupus Erythematosus: The Latin American Landscape.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From the Department of Immunology and Rheumatology, and Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; Department of Rheumatology, Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico; Department of Rheumatology, Hospital Universitario Dr. José E. González, Monterrey, Mexico; Department of Internal Medicine, Hospital Metropolitano Vivian Pellas, Managua, Nicaragua; Department of Rheumatology, Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador; Department of Rheumatology, Instituto Mexicano del Seguro Social, Guadalajara, Mexico; Department of Rheumatology, Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Mexico; Department of Internal Medicine, Hospital Universitario de la Samaritana, Bogotá, Colombia. J. Merayo-Chalico, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; A. Barrera-Vargas, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; S. Morales-Padilla, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; R. Reyna-De la Garza, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; R. Vázquez-Rodríguez, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; J. Campos-Guzmán, MD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; J. Alcocer-Varela, PhD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; M. Sotomayor, MD, Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán; C. Abud-Mendoza, MD, Department of Rheumatology, Hospital Central Dr. Ignacio Morones Prieto; M. Martínez-Martínez, MD, Department of Rheumatology, Hospital Central Dr. Ignacio Morones Prieto; I. Colunga-Pedroza, MD, Department of Rheumatology, Hospital Universitario; C. Uriarte-Hernández, MD, Department of Internal Medicine, Hospital Metropolitano Vivian Pellas; R. Acosta-Hernández, MD, Department of Rheumatology, Instituto Salvadoreño del Seguro Social; D. Fajardo, MD, Department of Rheumatology, Instituto Mexicano del Seguro Social; C. García-García, MD, Department of Rheumatology, Hospital General de Mexico; D. Padilla-Ortíz, MD, Department of Internal Medicine, Hospital Universitario de la Samaritana; D. Gómez-Martín, PhD, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Address correspondence to D. Gómez-Martín, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Tlalpan 14080, Mexico City, Mexico. E-mail: Accepted for publication September 11, 2018.

Objective: The aim of this study was to describe the prevalence of erectile dysfunction (ED), as well as associated demographic and clinical features, in men with systemic lupus erythematosus (SLE), by means of a systematic, standardized evaluation.

Methods: We performed a transversal study in 8 tertiary care centers in Latin America. We included male patients ≥ 16 years who fulfilled ≥ 4 American College of Rheumatology criteria for SLE and had regular sexual activity, and evaluated them with the International Index of Erectile Function-5 questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180292DOI Listing
January 2019

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From the Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping; Department of Medicine, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm; Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund; Unit for Clinical Therapy Research (ClinTRID), Karolinska University, Stockholm, Sweden; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario; Division of Rheumatology, Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec; Division of Rheumatology, Cumming School of Medicine - University of Calgary, Calgary, Alberta; Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea; Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham; Centre for Rheumatology Research, University College, London; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, King's College London School of Medicine, London; Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Foundation Trust, Manchester, UK; Cedars-Sinai/David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Department of Medicine, State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Feinstein Institute for Medical Research, Manhasset, New York; Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania; Northwestern University and Feinberg School of Medicine, Chicago, Illinois; Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia; University of California San Diego School of Medicine, La Jolla, California; Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA; Department of Rheumatology, Center for Rheumatology Research Fossvogur Landspitali University Hospital, Reyjkavik, Iceland; Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Cruces, BioCruces Health Research Institute, University of the Basque Country, Barakaldo; Josep Font Autoimmune Diseases Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Rheumatology, Kantousspital, Schaffhausen, Switzerland. This work was supported by grants from the Swedish Rheumatism Association, the County Council of Östergötland, the Swedish Society of Medicine, the King Gustaf V and Queen Victoria's Freemasons foundation, and the King Gustaf V's 80-year anniversary foundation. Dr. Fortin holds a Canada Research Chair on Systemic Autoimmune Rheumatic Diseases. Dr. Bae's work was supported in part by an unrestricted grant (Hanyang University 201600000001387). Dr. Gordon's work was supported by Lupus UK and the NIHR/Wellcome Trust Clinical Research Facility. The Hopkins Lupus Cohort is supported by the US National Institutes of Health (NIH; grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Bruce is supported by Arthritis Research UK, the NIHR Manchester Biomedical Research Centre and the NIHR/Wellcome Trust Clinical Research Facility at Manchester University National Health Service (NHS) Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Dr. Jacobsen is supported by the Danish Rheumatism Association (A1028). Dr. Dooley's work was supported by NIH grant RR00046. L. Wirestam, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; H. Enocsson, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; T. Skogh, MD, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; L. Padyukov, MD, PhD, Department of Medicine, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital; A. Jönsen, MD, PhD, Department of Clinical Sciences Lund, Section of Rheumatology, Lund University; M.B. Urowitz, MD, FRCPC, Professor of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; J. Romero-Diaz, MD, MSc, Instituto Nacional de Ciencias Médicas y Nutrición; S.C. Bae, MD, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; P.R. Fortin, MD, MPH, FRCPC, Professor of Medicine, Division of Rheumatology, CHU de Québec - Université Laval; J. Sanchez-Guerrero, MD, MSc, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; A.E. Clarke, MD, MSc, Division of Rheumatology, Cumming School of Medicine-University of Calgary; S. Bernatsky, MD, PhD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University Health Centre; C. Gordon, MD, Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham; J.G. Hanly, MD, Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University; D. Wallace, MD, Cedars-Sinai/David Geffen School of Medicine, University of California Los Angeles; D.A. Isenberg, MD, Centre for Rheumatology Research, University College London; A. Rahman, MD, PhD, Centre for Rheumatology Research, University College London; J. Merrill, MD, Department of Clinical Pharmacology, Oklahoma Medical Research Foundation; E. Ginzler, MD, PhD, Department of Medicine, SUNY Downstate Medical Center; G.S. Alarcón, MD, MPH, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; W.W. Chatham, MD, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M. Petri, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; M. Khamashta, MD, Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, King's College London School of Medicine; C. Aranow, MD, Feinstein Institute for Medical Research; M. Mackay, MD, Feinstein Institute for Medical Research; M.A. Dooley, MD, MPH, Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina; S. Manzi, MD, MPH, Autoimmunity Institute, Allegheny Health Network; R. Ramsey-Goldman, MD, DrPH, Northwestern University and Feinberg School of Medicine; O. Nived, MD, PhD, Department of Clinical Sciences Lund, Section of Rheumatology, Lund University; K. Steinsson, MD, Department of Rheumatology, Center for Rheumatology Research Fossvogur Landspitali University Hospital; A. Zoma, MD, Lanarkshire Centre for Rheumatology, Hairmyres Hospital; G. Ruiz-Irastorza, MD, Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Cruces, BioCruces Health Research Institute, University of the Basque Country; S. Lim, MD, MPH, Division of Rheumatology, Emory University School of Medicine; K. Kalunian, MD, University of California San Diego School of Medicine; M. Inanc, MD, Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University; R. van Vollenhoven, MD, ClinTRID, Karolinska University; M. Ramos-Casals, MD, Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic; D.L. Kamen, MD, Division of Rheumatology, Medical University of South Carolina; S. Jacobsen, MD, DMSc, Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital; C. Peschken, MD, FRCPC, Associate Professor of Medicine, Department of Medicine and Community Health Sciences, University of Manitoba; A. Askanase, MD, MPH, Division of Rheumatology, Columbia University Medical Center; T. Stoll, MD, Department of Rheumatology, Kantousspital; I.N. Bruce, MD, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Foundation Trust; J. Wetterö, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; C. Sjöwall, MD, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University. Address correspondence to Dr. L. Wirestam, AIR/Rheumatology, Department of Clinical and Experimental Medicine, Campus US, Linköping University, SE-581 85 Linköping, Sweden. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 4, 2018.

Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes.

Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180713DOI Listing
January 2019

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From the Division of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria; Division of Rheumatology, Hospital Universitario de Canarias, Tenerife; Division of Rheumatology, Hospital Insular, Las Palmas de Gran Canaria; Central Laboratory Division, Hospital Universitario de Canarias, Tenerife; Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria; CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Investigacíon Sanitaria (IDIVAL); Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL; Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL; School of Medicine, University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This work was supported by a grant to IFA from the Spanish Ministry of Health, Subdirección General de Evaluación y Fomento de la Investigación, Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 and by Fondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias, FIS PI14/00394, PI17/00083). Prof. González-Gay's research was supported by European Union FEDER funds and by the Fondo de Investigación Sanitaria (grants PI06/0024, PS09/00748, PI12/00060 and PI15/00525) of the Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain). It was also partially supported by RETICS Programs RD12/0009 (RIER), RD12/0009/0013, and RD16/0012 from the Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain). J.C. Quevedo-Abeledo, MD, Division of Rheumatology, Hospital Doctor Negrín; I. Rúa-Figueroa, MD, PhD, Division of Rheumatology, Hospital Doctor Negrín; H. Sánchez-Pérez, MD, Division of Rheumatology, Hospital Universitario de Canarias; B. Tejera-Segura, MD, Division of Rheumatology, Hospital Insular; A. de Vera-González, MD, Central Laboratory Division, Hospital Universitario de Canarias; A. González-Delgado, MD, Central Laboratory Division, Hospital Universitario de Canarias; J. Llorca, MD, PhD, Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBERESP, IDIVAL; M.A. González-Gay, MD, PhD, Division of Rheumatology, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, and School of Medicine, University of Cantabria, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand; I. Ferraz-Amaro, MD, PhD, Division of Rheumatology, Hospital Universitario de Canarias. Drs. M.A. González-Gay and I. Ferraz-Amaro shared senior authorship. Address correspondence to Dr. I. Ferraz-Amaro, Division of Rheumatology, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain. E-mail: Accepted for publication September 21, 2018.

Objective: Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180881DOI Listing
January 2019

Genetic Versus Non-genetic Drivers of SLE: Implications of IRF5 Dysregulation in Both Roads Leading to SLE.

Authors:
Betsy J Barnes

Curr Rheumatol Rep 2019 Jan 15;21(1). Epub 2019 Jan 15.

Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, Northwell Health, Feinstein Institute for Medical Research, Hofstra-Northwell School of Medicine, 350 Community Dr, Hempstead, NY, 11030, USA.

Purpose Of Review: Systemic lupus erythematosus (SLE) is characterized by a breakdown of immune tolerance, resulting in inflammation and tissue destruction. While the primary causes of SLE are still obscure, the disorder is highly heritable. Genetic risk variants, on their own, are rarely causal or fully explain disease pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-019-0803-3DOI Listing
January 2019

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

J Clin Invest 2019 Jan 15. Epub 2019 Jan 15.

Background/purpose: Plasmacytoid dendritic cells (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds BDCA2, a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in healthy volunteers (HV) and patients with SLE with active cutaneous disease as well as proof of biological activity and preliminary clinical response in the SLE cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI124466DOI Listing
January 2019

Association between Human Leukocyte Antigens with Autoimmune Diseases: Diagnostic Approach.

Curr Rheumatol Rev 2019 Jan 15. Epub 2019 Jan 15.

Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz. Iran.

Background: The process of antigen presentation to immune cells is an undeniable contributor to pathogenesis of autoimmune diseases. Different studies have indicated several factors that are related to autoimmunity. Human leukocyte antigens (HLAs) are among such factors, which have a key role in autoimmunity because of their involvement in antigen presentation process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573397115666190115143226DOI Listing
January 2019
1 Read

Ultrasound measurement of knee synovial fluid during external pneumatic compression.

J Orthop Res 2019 Jan 15. Epub 2019 Jan 15.

Department of Medicine Rheumatology Division National Jewish Health.

Synovial fluid based biomarker research has been limited by the small volumes of synovial fluid from the knees of some patients. We used ultrasound (US) to determine if synovial fluid could be displaced into an access port during pneumatic compression to 100 mmHg. Forty knees from thirty-seven consecutive arthritis patients with rheumatoid arthritis -25, osteoarthritis -8, psoriatic arthritis -2, and 1 each with systemic lupus erythematosus and gout were evaluated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jor.24216
Publisher Site
http://dx.doi.org/10.1002/jor.24216DOI Listing
January 2019
1 Read

Chilblain Lupus with Nail Involvement: A Case Report and a Brief Overview.

Skin Appendage Disord 2018 Nov 3;5(1):42-45. Epub 2018 May 3.

Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Chilblain lupus erythematosus is a rare, chronic variant of cutaneous lupus erythematosus that occurs during cold or damp periods on the hands, fingers, or feet. It is often associated with other forms of cutaneous lupus and about 20% of patients develop systemic lupus erythematosus. Various medications have been put forward, including steroids, mycophenolate mofetil, calcium channel blockers, and hydroxychloroquine, but the symptoms do not remit completely. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323373PMC
November 2018

[Etiologies and risk factors for young people with intracerebral hemorrhage].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 Nov;43(11):1246-1250

Department of Geriatrics Neurology, Xiangya Hospital, Central South University, Changsha 410008, China.

Objective: To determine the etiologies and risk factors of intracerebral hemorrhage in young people.
 Methods: A total of 401 young patients with intracerebral hemorrhage were enrolled, and they were assigned into a 20-29 , a 30-39, and a 40-45 age group. The differences of various etiologies and risk factors among the three groups were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2018.11.013DOI Listing
November 2018

Haemophagocytic lymphohistiocytosis with collapsing lupus podocytopathy as an unusual manifestation of systemic lupus erythematosus with APOL1 double-risk alleles.

BMJ Case Rep 2019 Jan 14;12(1). Epub 2019 Jan 14.

Division of Nephrology, Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine, Bronx, New York, USA.

Haemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening syndrome caused by excessive immune activation. Secondary HLH has been described in autoimmune diseases. We detail the case of a 28-year-old African American woman who developed HLH in the setting of systemic lupus erythematosus with collapsing lupus podocytopathy superimposed on mesangial proliferative lupus nephritis class II. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227860DOI Listing
January 2019

Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.

BMJ Case Rep 2019 Jan 14;12(1). Epub 2019 Jan 14.

Internal Medicine and Infectious Disease Department, Centre Hospitalier Sud Ile de France, Melun, France.

Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders. We report the case of a 44-year-old woman admitted with pancytopenia and clinical features of systemic lupus erythematosus, Sjogren's syndrome and antiphospholipid antibodies syndrome. Bone marrow biopsy showed decreased global cells and an increase of reticulin fibres on argentic coloration, consistent with myelofibrosis. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22752
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-227520DOI Listing
January 2019
1 Read

Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus.

BMJ Case Rep 2019 Jan 14;12(1). Epub 2019 Jan 14.

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.

A 45-year-old man with a history of systemic lupus erythematosus presented with progressive weakness and areflexia. Electromyogram revealed reduced motor and sensory amplitudes without demyelinating features. He was clinically diagnosed with the acute motor and sensory axonal neuropathy variant of Guillain-Barré syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226634DOI Listing
January 2019

Long-term outcomes in lupus patients receiving different renal replacement therapy.

J Microbiol Immunol Infect 2019 Jan 4. Epub 2019 Jan 4.

Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Background/purpose: To compare the long-term outcomes and survival rates of patients with end stage renal disease (ESRD) caused by lupus nephritis who received three different modalities of renal replacement therapy, including hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT).

Methods: We retrospectively analyzed 94 patients with ESRD caused by lupus nephritis. Among these, 42 received HD, 12 received PD, and 40 underwent KT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmii.2018.12.010DOI Listing
January 2019

Haemophagocytic syndrome in Systemic Lupus Erythematosus - clues to an early diagnosis.

Acta Reumatol Port 2018 Oct-Dec;43(4):318-320

Centro Hospitalar São João.

Macrophage activation syndrome (MAS) is a rare life-threatening condition that involves excessive activation of inflammatory cells and overproduction of different cytokines. It is characterized by persistent fever, hepatosplenomegaly, cytopenias and coagulopathy. Other prominent features are hyperferritinemia and findings of activated macrophages in haemopoietic organs, often associated with multi-organ impairment. Read More

View Article

Download full-text PDF

Source
January 2019

SLICC classification criteria for juvenile systemic lupus erythematosus: a cross sectional study.

Acta Reumatol Port 2018 Oct-Dec;43(4):279-283

Universidade Federal de São Paulo.

Objectives: to verify the sensitivity and specificity of the criteria for systemic lupus erythematosus, proposed by the Systemic Lupus International Collaborating Clinics (SLICC) and compare it to the ACR lupus criteria, in a pediatric population.

Patients And Methods: this is an observational cohort study, with a descriptive analysis of data from a Pediatric Rheumatology center, including 23 patients with Juvenile Systemic Lupus Erythematosus (jSLE) and a control group of 24 patients with Juvenile Idiopathic Arthritis (JIA), both groups recently diagnosed and virgin of treatment. Information on signs and symptoms was obtained on the diagnostic consult, and the ACR and SLICC criteria were applied to both groups. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Polyomavirus BK, BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis.

PLoS One 2019 14;14(1):e0210633. Epub 2019 Jan 14.

Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Objective: Lupus nephritis (LN) frequently progresses to end-stage renal disease. Finding a biomarker for LN and a predictor for the development of chronic kidney disease (CKD) is important for patients with systemic lupus erythematosus (SLE).

Methods: Ninety patients with SLE were divided into biopsy-proven LN (n = 54) and no kidney involvement (non-LN) (n = 36) groups and followed up for 54 months. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210633PLOS
January 2019

Lupus and Left Ventricular Assist Devices: High-Risk for Bleeding?

ASAIO J 2019 Jan 9. Epub 2019 Jan 9.

Section of Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio.

Continuous-flow left ventricular assist devices (LVAD) have become an increasingly utilized treatment strategy for patients with end-stage heart failure. Despite the improved outcomes evident with current generation pumps, proper patient selection remains crucial to minimize the risk of potential adverse events. The evolving use of these devices as destination therapy (DT) has led to growing numbers of patients with higher risk comorbid conditions being evaluated as potential LVAD candidates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MAT.0000000000000946DOI Listing
January 2019

Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus.

Autoimmun Rev 2019 Jan 11. Epub 2019 Jan 11.

GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina traslacional. Fundación Valle del Lili, Univesidad Icesi, Colombia; Laboratory of immunology, Fundación Valle del Lili, Cali, Colombia. Electronic address:

The current existing therapies for severe cases of systemic lupus erythematosus (SLE) patients are still limited. Intravenous immunoglobulin (IVIGs), which are purified from the plasma of thousands of healthy human donors, have been profiled as efficacious and life-saving options for SLE patients refractory to conventional therapy. The specific mechanism of action by which IVIGs generate immunomodulation in SLE is not currently understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.002DOI Listing
January 2019

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

Autoimmun Rev 2019 Jan 10. Epub 2019 Jan 10.

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy. Electronic address:

Graves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.001DOI Listing
January 2019
4 Reads

Innate immune-responses and their role in driving autoimmunity.

Autoimmun Rev 2019 Jan 10. Epub 2019 Jan 10.

Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel. Electronic address:

Autoimmunity and autoimmune diseases were always considered to be driven mainly by adaptive immune responses, namely by auto-reactive B and T cell over-activity. The continuous stimulation of dendritic cells by autoantigens increases B cell activity, driving auto-reactive B cells to increase the production of autoantibodies and of pro-inflammatory cytokines. On the other hand, a subset of dendritic cells is established being of tolerogenic properties thus becoming important in maintaining self-tolerance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.005DOI Listing
January 2019

Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view.

Autoimmun Rev 2019 Jan 10. Epub 2019 Jan 10.

Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Italy.

Systemic lupus erythematosus (SLE) is a connective tissue disease that involves multiple organs. Ocular structures and visual pathways can be affected in SLE because of disease-related eye involvement or drug toxicity. All the part of the eye may be interested with an external, anterior involvement, responsible of the dry eye disease, or posterior (retina) and neuro-ophtalmic manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.09.011DOI Listing
January 2019

Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis.

J Cyst Fibros 2019 Jan 9. Epub 2019 Jan 9.

Department of Infectious Diseases, College of Veterinary Medicine, The University of Georgia, Athens, GA, USA. Electronic address:

Cystic fibrosis (CF) airway disease is characterized by the long-term presence of neutrophil granulocytes. Formation of neutrophil extracellular traps (NETs) and/or autoantibodies directed against extracellular components of NETs are possible contributors to neutrophil-mediated lung damage in CF. The goal of this study was to measure their levels in CF adults compared to healthy controls and subjects with rheumatologic diseases known to develop NET-related autoantibodies and pathologies, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15691993183097
Publisher Site
http://dx.doi.org/10.1016/j.jcf.2018.12.010DOI Listing
January 2019
1 Read

Human Low-Affinity IgG Receptor FcγRIIA Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in Systemic Lupus Erythematosus.

J Thromb Haemost 2019 Jan 14. Epub 2019 Jan 14.

Department of Medicine, Division of Cardiology, NYU Langone Medical Center, NY.

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease associated with an elevated risk for premature cardiovascular disease. Platelets express receptors contributing to inflammation and immunity including FcγRIIA, the low affinity receptor of the Fc portion of IgG antibodies. The variation at a single amino acid substitution, H131R, in the extracellular binding domain alters the affinity for IgG, which may account for individual variation in platelet activity and platelet mediated disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14385DOI Listing
January 2019

The relationship between pemphigus and systemic lupus erythematosus: a cross-sectional study, systematic review, and meta-analysis.

Immunol Res 2019 Jan 14. Epub 2019 Jan 14.

Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.

The coexistence of pemphigus and systemic lupus erythematosus (SLE) had been reported anecdotally. Anti-desmoglein (Dsg)1 and anti-Dsg3 antibodies were detected concomitantly with antinuclear autoantibodies among blood donors. The aim of the current study was to study the association between pemphigus and SLE in Israeli patients and to synthesize existing data on this association in the current literature. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12026-019-9065-4
Publisher Site
http://dx.doi.org/10.1007/s12026-019-9065-4DOI Listing
January 2019
2 Reads

Cell Senescence in Lupus.

Curr Rheumatol Rep 2019 Jan 14;21(2). Epub 2019 Jan 14.

Allergy Immunology Rheumatology Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Purpose Of Review: The concept of cellular senescence has been evolving. Although originally proposed based on studies of serum-driven replication of cell lines in vitro, it is now clear that cellular senescence occurs in vivo. It has also become clear that cellular senescence can be triggered by a number of stimuli such as radiation, chemotherapy, activation of oncogenes, metabolic derangements, and chronic inflammation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11926-019-0800-6
Publisher Site
http://dx.doi.org/10.1007/s11926-019-0800-6DOI Listing
January 2019
1 Read

Abnormal amplitude of low frequency fluctuation and functional connectivity in non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study.

Neuroradiology 2019 Jan 12. Epub 2019 Jan 12.

Department of Radiology, Affiliated Hospital of North Sichuan Medical College, 63#, Wenhua Road, Shunqing District, Nanchong, 637000, Sichuan, China.

Purpose: To explore the amplitude of low frequency fluctuation (ALFF) and functional connectivity (FC) disorders in non-neuropsychiatric systemic lupus erythematosus (non-NPSLE) patients by resting-state functional magnetic resonance imaging (rs-fMRI) and to study whether there are some clinical biomarkers that can be used to monitor the brain dysfunction.

Methods: Based on the rs-fMRI data of 36 non-NPSLE patients and 30 normal controls, we first obtained the regions with abnormal ALFF signals in non-NPSLE patients. Then, by taking these areas as seed regions of interest (ROIs), we calculated the FC between ROIs and the whole brain to assess the network-level alterations. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00234-018-2138-6
Publisher Site
http://dx.doi.org/10.1007/s00234-018-2138-6DOI Listing
January 2019
1 Read

Decreased serum/plasma vitamin D levels in SLE patients: A Meta-analysis.

Curr Pharm Des 2019 Jan 11. Epub 2019 Jan 11.

Department of Nephrology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui. China.

Background and Objective:The evidence regarding the association between serum/plasma vitamin D (VitD) concentrations and systemic lupus erythematosus (SLE) is inconsistent. The study was based on relevant results from literatures that were identified and evaluated. The aim of this meta-analysis is to determine circulating VitD in SLE patients and explore influencing factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612825666190111145848DOI Listing
January 2019

Jan Gösta Waldenström and rheumatology.

Authors:
Frank A Wollheim

Ann Rheum Dis 2019 Jan 12. Epub 2019 Jan 12.

Department of Clinical Sciences Lund, Rheumatology, Medical Faculty, Lund University, Lund 22185, Sweden

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-21483
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2018-214838DOI Listing
January 2019
1 Read

Current challenges in the development of new treatments for lupus.

Ann Rheum Dis 2019 Jan 12. Epub 2019 Jan 12.

RILITE Research Institute, Charlottesville, Virginia, USA.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214530DOI Listing
January 2019

Mechanic hands: clinical and capillaroscopy manifestations of patients with connective tissue diseases presented with and without mechanic hands.

Clin Rheumatol 2019 Jan 12. Epub 2019 Jan 12.

Division of Rheumatology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.

Objectives: The condition known as 'Mechanic's Hands' is a thickened, hyperkeratotic eruption, which is bilaterally symmetric along the fingers, and often occurs in patients with some connective tissue diseases. Nail fold capillaroscopy is a non-invasive technique for evaluation of connective tissue diseases. We evaluated the prevalence of mechanic hands in patients with connective tissue diseases and compared the clinical manifestations and capillaroscopic changes in the patients with and without mechanic hands. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-04422-zDOI Listing
January 2019

Prolactin, autoimmunity, and motherhood: when should women avoid breastfeeding?

Clin Rheumatol 2019 Jan 11. Epub 2019 Jan 11.

Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv University, 5265601, Tel Hashomer, Israel.

The sexual dimorphic prevalence of autoimmunity represents one of the most alluring observations among the mosaic of autoimmunity. Sex hormones are believed to be a mainstay of this asymmetry. The greater prevalence of autoimmunity among fertile women, disease onset/relapses during pregnancy, and postpartum are some of the points that support this theory. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-018-04415-y
Publisher Site
http://dx.doi.org/10.1007/s10067-018-04415-yDOI Listing
January 2019
1 Read

Mother-child histocompatibility and risk of rheumatoid arthritis and systemic lupus erythematosus among mothers.

Genes Immun 2019 Jan 12. Epub 2019 Jan 12.

Genetic Epidemiology and Genomics Lab, Division of Epidemiology, School of Public Health, University of California Berkeley, 324 Stanley Hall, Berkeley, CA, 94720-3220, USA.

The study objective was to test the hypothesis that having histocompatible children increases the risk of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), possibly by contributing to the persistence of fetal cells acquired during pregnancy. We conducted a case control study using data from the UC San Francisco Mother Child Immunogenetic Study and studies at the Inova Translational Medicine Institute. We imputed human leukocyte antigen (HLA) alleles and minor histocompatibility antigens (mHags). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41435-018-0055-7
Publisher Site
http://dx.doi.org/10.1038/s41435-018-0055-7DOI Listing
January 2019
4 Reads
2.913 Impact Factor

Long-Term Prognosis of Patients with Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study.

Eur Respir J 2019 Jan 11. Epub 2019 Jan 11.

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

This study aimed to identify the long-term clinical outcomes and prognostic factors of patients with SLE-associated PAH confirmed by right heart catheterisation. A multicenter prospective cohort of SLE-associated PAH was established. Baseline and follow-up records were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.00081-2018DOI Listing
January 2019
1 Read
7.636 Impact Factor

Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls.

J Eur Acad Dermatol Venereol 2019 Jan 11. Epub 2019 Jan 11.

Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: Hair and scalp involvement in systemic lupus erythematosus (SLE) can manifest as scarring alopecia, non-scarring alopecia or scalp/hair shaft changes without apparent hair loss. While trichoscopic signs in chronic cutaneous lupus are well estabished, data on SLE patients with normal-looking or non-scarring scalp are limited.

Objectives: To investigate trichoscopic features of SLE patients without chronic cutaneous scalp lesions and compare the findings with normal controls, as well as determine which feature associates with systemic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15421DOI Listing
January 2019

CALD1, CNN1, and TAGLN identified as potential prognostic molecular markers of bladder cancer by bioinformatics analysis.

Medicine (Baltimore) 2019 Jan;98(2):e13847

Department of Urology, the Affiliated Zhaotong Hospital of Kunming Medical University, Zhaotong, Yunnan Province, China.

Background: Bladder cancer (BC) is one of the most common malignant neoplasms in the genitourinary tract. We employed the GSE13507 data set from the Gene Expression Omnibus (GEO) database in order to identify key genes related to tumorigenesis, progression, and prognosis in BC patients.

Methods: The data set used in this study included 10 normal bladder mucosae tissue samples and 165 primary BC tissue samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013847DOI Listing
January 2019
1 Read

Inflammatory bowel diseases and primary immunodeficiency diseases.

Immunol Med 2019 Jan 11:1-8. Epub 2019 Jan 11.

a Department of Child Health and Development, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.

Recent advances in molecular biology have provided important insights into the genetic background of various inflammatory diseases. In particular, genome-wide association studies of inflammatory diseases have revealed genetic loci that play critical roles in the pathology of inflammation. Whole-exome and whole-genome sequencing analyses have also identified more than 300 causative genes for primary immunodeficiency diseases (PIDs). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/25785826.2018.1
Publisher Site
http://dx.doi.org/10.1080/25785826.2018.1556025DOI Listing
January 2019
1 Read

Serum Transforming Growth Factor-Beta 1 Level in Egyptian Systemic Lupus Erythematosus Patients.

Arch Rheumatol 2018 Sep 31;33(3):358-366. Epub 2018 Jul 31.

Department of Internal Medicine, Cairo University, Cairo, Egypt.

Objectives: This study aims to assess the role of transforming growth factor-beta 1 (TGF-β1) in systemic lupus erythematosus (SLE).

Patients And Methods: The study included 40 female SLE patients (mean age 25.5±6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ArchRheumatol.2018.6405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328217PMC
September 2018

Epidemiology, characterization and diagnosis of neuropsychiatric events in systemic lupus erythematosus.

Expert Rev Clin Immunol 2019 Jan 11. Epub 2019 Jan 11.

b Laboratory of Autoimmune Diseases, School of Medical Science , University of Campinas , Campinas , SP 13083-872 , Brazil.

Introduction: Neuropsychiatric systemic lupus erythematosus (NPSLE) is characterized by a heterogeneity of clinical manifestations. The absence of diagnostic criteria and the lack of clinical trials is a challenge in clinical practice. Areas covered: A literature review was performed to describe epidemiology, characterization (clinical, immunological and imaging), diagnosis and treatment of NPSLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1564040DOI Listing
January 2019

[Recognize rare diseases on the skin].

Internist (Berl) 2019 Jan 10. Epub 2019 Jan 10.

Klinik für Dermatologie und Allergologie, Universitätsklinikum Marburg (UKGM), Baldingerstr. 1, 35043, Marburg, Deutschland.

The correct interpretation of skin manifestations can facilitate the diagnosis of many rare systemic diseases. Such manifestations can be due to autoimmune diseases (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-018-0548-5DOI Listing
January 2019

Seizure and Acute Vision Loss in a Filipino Lupus Patient: A Case of Posterior Reversible Encephalopathy Syndrome with Intraparenchymal Hemorrhage.

Case Rep Med 2018 9;2018:4238676. Epub 2018 Dec 9.

Section of Rheumatology, Department of Medicine, UP-Philippine General Hospital, Manila, Philippines.

Posterior reversible encephalopathy syndrome (PRES) is a rare and poorly understood neurologic condition that has been described in some patients with systemic lupus erythematosus (SLE). Intracerebral hemorrhage is a unique and atypical presentation of PRES and has been described only in a small number of patients with SLE. We present the case of a 33-year-old female, diagnosed with SLE and active nephritis, who was admitted for seizures. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crim/2018/4238676/
Publisher Site
http://dx.doi.org/10.1155/2018/4238676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304919PMC
December 2018
2 Reads

Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus.

Acta Med Indones 2018 Oct;50(4):343-345

Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.

A 38-year-old woman presented with general weakness and vaginal bleeding. One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia) and was given oral steroid as maintenance therapy. Her serology examination was negative for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Read More

View Article

Download full-text PDF

Source
October 2018

Acute Appendicitis in a Patient with Systemic Lupus Erythematosus.

Acta Med Indones 2018 Oct;50(4):332-335

Department of Internal Medicine, Faculty of Medicine, Airlanggan University - dr. Soetomo Hospital, Surabaya, Indonesia.

Systemic lupus erythematosus (SLE) is a chronic excacerbative autoimmune disease with wide clinical spectrum. Gastrointestinal manifestasion is a frequent clinical manifestasion seen in SLE. Management with glucocorticoid and non-steroid anti-inflammatory drugs (NSAID) can mask the gastrointestinal symptoms in patient with SLE. Read More

View Article

Download full-text PDF

Source
October 2018
1 Read

The role of 5-methoxytryptophan in pediatric-onset lupus nephritis: A retrospective cohort study.

J Microbiol Immunol Infect 2018 Dec 19. Epub 2018 Dec 19.

Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Background: This clinical study investigates the role of 5-methoxytryptophan (5-MTP) in pediatric systemic lupus erythematosus (SLE), with a particular interest in lupus nephritis (LN).

Patients And Methods: One hundred ten children with SLE were enrolled in the cohort study. Among the patients, seventy-seven (70%) had active LN and thirty-three (30%) were not present with LN during their first visit to the clinic. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S16841182183007
Publisher Site
http://dx.doi.org/10.1016/j.jmii.2018.12.003DOI Listing
December 2018
1 Read